South-Spike: Variants of SARS-CoV-2 Causing COVID-19 in Africa
Study Details
Study Description
Brief Summary
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic.
The research will combine retrospective and prospective approaches to determine the evolutionary dynamics of the virus since the start of the pandemic. It is planned to sequence the entire Spike protein gene for 1550 viruses and make 300 entire genomes. This work will be supplemented by antibody seroneutralization and respiratory transcriptomics tests, in order to estimate the immuno-virological response of the COVID-19 disease associated with the identified SARS-CoV-2 variants.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Retrospective 12000 participants positive for SARS-COV-2 |
Diagnostic Test: RT PCR
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Other Names:
|
Prospective 600 participants positive for SARS-COV-2 |
Diagnostic Test: RT PCR
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of SARS-CoV-2 sequences generated partially and in whole genome [Through study completion, an average of 1 year.]
This outcome represent our main gaol and will include sequences that were partially generated in the Spike proteine and full genomes as well. Our current target is 1550 sequences.
Secondary Outcome Measures
- Number of individuals tested positive for COVID-19 [Up to six months]
This outcome will be focused on the number of persons that will be tested positive for COVID-19 throughout the study, using SARS-CoV-2 rapid antigen tests. We planned to screen 12000 individuals overall in the six participating countries.
- Number of new SARS-CoV-2 variants identify [Through study completion, an average of 1 year.]
This outcome represents the number of new viruses that are identified at the end of the study and have not been reported previously.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Major subject (cf. country)
-
Presenting for a SARS-COV-2 diagnosis, whether symptomatic or not
-
Not objecting to participating in the research
Exclusion Criteria:
- NA
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Centre de Référence pour les pathogènes émergents et réémergent | Bobo-Dioulasso | Burkina Faso | BP 2161 | |
2 | Centre Hospitalier Universitaire la Référence Nationale (CHU-RN) | N'Djamena | Chad | BP : 130 | |
3 | Laboratoire National de Santé Publique Brazzaville | Brazzaville | Congo | ||
4 | CIRBA | Abidjan | Côte D'Ivoire | ||
5 | Unité Mixte de Recherche CIRMF-SSM | Libreville | Gabon | 20404 | |
6 | SEREFO | Bamako | Mali | BP: 1805 |
Sponsors and Collaborators
- ANRS, Emerging Infectious Diseases
- Institut de Recherche pour le Developpement
- Institut National de la Santé Et de la Recherche Médicale, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ANRS 0136s